GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OCSE:ALK B) » Definitions » Deferred Tax

Alk-Abello A/S (OCSE:ALK B) Deferred Tax : kr184 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello A/S Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Alk-Abello A/S's change in deferred tax for the three months ended in Mar. 2024 was kr77 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was kr184 Mil.

Alk-Abello A/S Deferred Tax Historical Data

The historical data trend for Alk-Abello A/S's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Deferred Tax Chart

Alk-Abello A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.00 76.00 60.00 112.00 161.00

Alk-Abello A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.00 23.00 38.00 46.00 77.00

Alk-Abello A/S Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr184 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello A/S Deferred Tax Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello A/S (OCSE:ALK B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OCSE:ALK B) » Definitions » Deferred Tax
Comparable Companies
OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:GMAB OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
AKBLF:USA ALKBc:UK 0OIR:UK 4AJ0:Germany
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Website
https://www.alk.net
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello A/S (OCSE:ALK B) Headlines

No Headlines